Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma
NCT04905602Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2021
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR-1905 in asthma (6 cohorts), sponsored by Hengrui Therapeutics. Primary endpoint: Adverse events. Started Jun 2021; status: completed.
02
Drugs
SHR-1905
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04905602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04905602.